Neurocrine Biosciences
Clinical trials sponsored by Neurocrine Biosciences, explained in plain language.
A biopharmaceutical company focused on neurological and endocrine disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for uncontrolled muscle movements: valbenazine trial targets stubborn TD symptoms Results expected Jan 2027 (estimated)
- New pill could tame involuntary twitching in mental health patients Results expected Feb 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
-
New hope for CAH: drug may slash steroid use
Disease control OngoingThis study tests a drug called crinecerfont in adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that requires lifelong steroid treatment. The goal is to see if crinecerfont can safely reduce the daily steroid dose needed while keeping hormone levels u…
Phase 3 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug valbenazine tested for Huntington's movement problems
Symptom relief By invitation onlyThis study looks at the long-term safety of valbenazine for people with Huntington disease who have involuntary jerking movements (chorea). It includes 7 participants from Canada who were in a previous valbenazine study. Everyone gets the drug, and researchers track side effects …
Phase 3 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC